HER2+ Breast Cancer | Specialty

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer

March 25th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Hurvitz Discusses Dramatic Advances in HER2+ Breast Cancer

March 23rd 2017

Sara Hurvitz, MD, discusses the amazing evolution in the available treatment options for patients with HER2-positive breast cancer.

Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast Cancer

March 22nd 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer

March 22nd 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer

March 19th 2017

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

March 16th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

Neoadjuvant Therapy Improves Breast Conservation Outlook

March 15th 2017

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.

HER2 Gene Testing Guidelines May Misclassify Patients

March 13th 2017

Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

March 11th 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

March 10th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

March 8th 2017

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Adjuvant Pertuzumab Succeeds in Phase III HER2+ Breast Cancer Trial

March 2nd 2017

Adding pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer, according to findings from the phase III APHINITY study.

Antibody-Drug Conjugates for TNBC

February 22nd 2017

Immunotherapy for TNBC

February 22nd 2017

BRCA1/2 Status and Homologous Repair Deficiency in TNBC

February 22nd 2017

Treating HER2+ Metastatic Breast Cancer

February 22nd 2017

Extended Adjuvant Therapy for HER2+ Early Breast Cancer

February 22nd 2017

HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer

February 22nd 2017

PI3K Inhibitors in HR+ Metastatic Breast Cancer

February 22nd 2017

Everolimus for HR+ Metastatic Breast Cancer

February 22nd 2017